116 results about "High risk patients" patented technology

The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

The invention relates to a method for the treatment of G250-antigen-expressing tumors, in particular renal clear cell carcinoma comprising the administration of G250-antigen-specific antibodies to high-risk patients diagnosed with non-metastasizing disease.

Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.

An accurate predictive model that identifies the patient / members within the healthcare system at high risk of hospital admission for a wide range of morbidities, or co-morbidities, and that allows subsequent intervention to manage those patients identified as high risk to an acceptable level. There is a further need for such a predictive model that focuses on specific groupings of conditions, e.g., behavioral health predictive modeling. There is also a need for a method that provides for intervention to manage the risk to the identified patients / members. One embodiment of the present invention discloses and claims a method of high-risk patient identification and management. In one aspect, the inventive method may comprise compiling a listing including all individuals with any primary behavioral health diagnosis over a specified time period; merging the listing with at least one data source to extract at least one behavioral health-related predictive factor; generating, based on at least one predictive model, a predictive output comprising the probability that the individuals listed will require a future behavioral health-related hospital admission; identifying the high-risk individuals from the predictive model output; and intervening with the high risk members to identify and modify, to the extent possible, the risk factors that place the member at high risk.

The invention relates to an electrohydraulic prostate tissue treatment probe, which comprises a probe pipe body, wherein a drainage channel, a water-injection channel, a gas-injection channel and a cathode channel are arranged in the probe pipe body along the axial direction; the front end of the probe pipe body is a guiding head; a positioning balloon is arranged behind the guiding head; an external cathode electrode is tightly wound on the probe pipe body on the rear side of the positioning balloon; a leading-out end is connected with a cathode plug through the cathode channel; an external anode electrode is arranged between the positioning balloon and the cathode electrode, is wound by one circle at least, and is kept in a certain interval from the cathode electrode; and the leading-out end is connected with an anode plug through the drainage channel. The probe has the advantages that the probe is large in treatment range, safe, reliable, free from damage to non-target organs, insusceptible to cause relapse and insusceptible to produce fibrous plaque hyperplasia and cicatricial stenosis, reduces cost, can effectively eliminate the hidden trouble of cross infection, enables patients to have good tolerance and slight adverse reaction, and is particularly suitable to treat elderly high-risk patients who suffer from prostatic hyperplasia and cannot tolerate operations and anesthesia.